New compound provides an observed 90% increase in the activation of the gene's activation in the animal's heart tissue

The University of Hawaii Cancer Center has developed a compound called Astaxanthin that turns on whats called the FOX03 'Longevity Gene' in mice. Their scientists measured an almost a 90% increase in the activation of the gene in the animals' heart tissue.

In a joint venture, The University of Hawaii John A. Burns School of Medicine ("JABSOM") and Cardax, Inc. ("Cardax") (OTCQB:CDXI), a Honolulu based life sciences company revealed their promising results toward a new anti-aging therapy

Dr. Bradley Willcox, MD, Professor and Director of Research at the Department of Geriatric Medicine, JABSOM, and Principal Investigator of the National Institutes of Health-funded Kuakini Hawaii Lifespan and Healthspan Studies states, "All of us have the FOXO3 gene, which protects against aging in humans," said. "But about one in three persons carry a version of the FOXO3 gene that is associated with longevity. By activating the FOXO3 gene common in all humans, we can make it act like the "longevity" version. Through this research, we have shown that Astaxanthin "activates" the FOXO3 gene," said Willcox.

"This preliminary study was the first of its kind to test the potential of Astaxanthin to activate the FOXO3 gene in mammals," said Dr. Richard Allsopp, PhD, Associate Professor, and researcher with the JABSOM Institute of Biogenesis Research.

Experiments with the mice the control group was fed regular food and the other group was either a low or high amount of Astaxanthin compound CDX-085 provided by Cardax. As expected the group with higher doses gained the greatest increase in the FOXO3 gene in their heart tissue. "We found a nearly 90% increase in the activation of the FOXO3 "Longevity Gene" in the mice fed the higher dose of the Astaxanthin compound CDX-085," said Dr. Allsopp.

"This groundbreaking University of Hawaii research further supports the critical role of Astaxanthin in health and why the healthcare community is embracing its use," said David G. Watumull, Cardax CEO. "We look forward to further confirmation in human clinical trials of Astaxanthin's role in aging."

"We are extremely proud of our collaborative efforts with Cardax on this very promising research that may help mitigate the effects of aging in humans," said Vassilis L. Syrmos, Vice President of Research at the University of Hawaii. "This is a great example of what the Hawaii Innovation Initiative is all about -- when the private sector and government join forces to build a thriving innovation, research, education and job training enterprise to help diversify the state's economy."

Life sciences company Cardax, Inc. looks forward to further confirmation in human clinical trials of Astanxanthin's potential role as an anti-aging therapy.

Dr. Michael J. Koch, Editor withwww.WorldHealth.net and for Dr. Ronald Klatz, DO, MD President of the A4M has 28,000 Physician Members, has trained over 150,000 Physicians, health professionals and scientists in the new specialty of Anti-aging medicine. Estimates of their patients numbering in the 100s of millions World Wide that are living better stronger, healthier and longer lives. A4M physicians are now providing advanced preventative medical care for over 100 Million individuals worldwide who now recognize that aging is no longer inevitable.

The rest is here:
Discovery of a New Compound Turns on a Longevity Gene in Mice - Anti Aging News